Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20626453 | 0.92 | SLC29A1 (0.52) | SLC29A1ADORA3TSHRCYP3A4NFKB1 | |
| SCHEMBL20626449 | 0.92 | SLC29A1 (0.52) | SLC29A1ADORA3TSHRCYP3A4NFKB1 | |
| SCHEMBL14714043 | 0.92 | SLC29A1 (0.52) | SLC29A1ADORA3TSHRCYP3A4NFKB1 | |
| SCHEMBL14713459 | 0.88 | SLC29A1 (0.48) | SLC29A1ADORA3TSHRALDH1A1 | |
| SCHEMBL14713445 | 0.87 | SLC29A1 (0.48) | SLC29A1ADORA3TSHRCYP3A4NFKB1 | |
| SCHEMBL14713454 | 0.85 | PAX8 (0.54) | SLC29A1ADORA3TSHRNFKB1BLM | |
| SCHEMBL20626278 | 0.80 | SLC29A1 (0.47) | SLC29A1ADORA3TSHRALDH1A1DNPH1 | |
| SCHEMBL20626279 | 0.80 | SLC29A1 (0.47) | SLC29A1ADORA3TSHRALDH1A1DNPH1 | |
| SCHEMBL14714122 | 0.80 | SLC29A1 (0.47) | SLC29A1ADORA3TSHRALDH1A1DNPH1 | |
| SCHEMBL20626494 | 0.80 | SLC29A1 (0.47) | SLC29A1ADORA3TSHRCYP3A4NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130045942-A1 | N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2013-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045942-A1 | N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF | ADORA2A, ADORA3, ADORA1 | SLC29A1 267/4885ADORA3 2/4885TSHR 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.